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Abstract
Objectives—Prior to antiretroviral treatment, HIV-infected children frequently developed
encephalopathy, resulting in debilitating morbidity and mortality. This is the first large study to
evaluate the impact of HAART and central nervous system (CNS)-penetrating antiretroviral
regimens on the incidence of HIV encephalopathy and survival after diagnosis of HIV
encephalopathy among perinatally infected children.
Design—A total of 2398 perinatally HIV-infected children with at least one neurological
examination were followed in a US-based prospective cohort study conducted from 1993 to 2007.
Methods—Trends in incidence rates over calendar time were described and Cox regression models
were used to estimate the effects of time-varying HAART and CNS-penetrating antiretroviral
regimens on HIV encephalopathy and on survival after diagnosis of HIV encephalopathy.
Results—During a median of 6.4 years of follow-up, 77 incident cases of HIV encephalopathy
occurred [incidence rate 5.1 cases per 1000 person-years, 95% confidence interval (CI) 4.0–6.3]. A
10-fold decline in incidence was observed beginning in 1996, followed by a stable incidence rate
after 2002. HAART regimens were associated with a 50% decrease (95% CI 14–71%) in the
incidence of HIV encephalopathy compared with non-HAART regimens. High CNS-penetrating
regimens were associated with a substantial survival benefit (74% reduction in the risk of death, 95%
CI 39–89%) after HIV encephalopathy diagnosis compared with low CNS-penetrating regimens.
Conclusion—A dramatic decrease in the incidence of HIV encephalopathy occurred after the
introduction of HAART. The use of HAART was highly effective in reducing the incidence of HIV
encephalopathy among perinatally infected children and adolescents. Effective CNS-penetrating
antiretroviral regimens are important in affecting survival after diagnosis of HIV encephalopathy.
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The first pediatric cases of HIV encephalopathy were reported in 1985 among children with
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AIDS [1–3]. The prevalence of HIVencephalopathy among this population varied from 30 to
50% and latency to HIV encephalopathy ranged from 2 months to 5 years [3,4]. Clinical
features of HIV encephalopathy include loss of or failure to attain developmental milestones,
impaired brain growth, and motor deficits [1–4]. Some children present with rapidly
progressive fatal disease, whereas others have stable phases interspersed with short periods of
neurological deterioration [1–3]. Given the level of morbidity and mortality associated with
this disease, HIV encephalopathy was added as an AIDS-defining condition in 1987 [5].
Studies of cerebrospinal fluid (CSF) from children with HIV encephalopathy found active and
persistent brain infection with HIV suggesting a need for antivirals that penetrate the blood–
brain barrier [3,6]. Drug manufacturers and independent studies have evaluated the penetration
of specific antiretroviral drugs into CSF [7]. To aid clinicians in antiretroviral therapy decision-
making for patients with neurological symptoms, this information has recently been used to
develop a drug ranking system based on a drug's ability to penetrate the central nervous system
(CNS) [7]. The clinical utility of these CNS-penetration-effectiveness ranks still needs to be
validated in pediatric populations and clinical studies examining neurological outcomes such
as HIV encephalopathy [7].
With yje advent of HAART, survival has increased [8,9]. The effect of such therapy on
neurological disease such as HIVencephalopathy, however, is less clear. Several studies [10–
13] have suggested a decreasing incidence of HIV encephalopathy. However, heterogeneity
in the time scales and study populations used make it difficult to assess trends and attribute
them to antiretroviral use.
The majority of studies examining the association between antiretroviral use and HIV
encephalopathy [14–17] have focused on the effect of antiretroviral therapy on improving
neuropsychological functioning after diagnosis of encephalopathy. One study [18] examined
the effect of antiretroviral therapy before diagnosis of encephalopathy but restricted their study
population to children with an eventual diagnosis of HIVencephalopathy. It found antiretroviral
therapy to be associated with a later age at diagnosis. Another study compared 13 children ever
diagnosed with HIV encephalopathy with 113 children never diagnosed with HIV
encephalopathy and found a significantly greater proportion of HAART use among the children
with a diagnosis of HIV encephalopathy [13]. The temporal relationship between HAART use
and diagnosis is unclear in this study and no multivariate analyses were conducted to adjust
for confounding by indication. Three recent studies [19–21] compared effect of early versus
deferred antiretroviral therapy on AIDS progression and/or mortality and found a higher
number of HIV encephalopathy cases among the groups that deferred therapy. Each of these
studies, however, only had a few HIV encephalopathy cases (range 3–9 cases) to compare
between their early and deferred treatment groups. No studies to date have quantified the effect
of antiretroviral use on the risk of HIV encephalopathy. Our study describes the incidence of
HIV encephalopathy between 1994 and 2006 among a cohort of perinatally HIV-infected
children enrolled in a large multicenter cohort study in the United States and evaluates the
effects of HAART and CNS-penetrating antiretroviral regimens on the incidence of
encephalopathy. It further assesses the effects of HAART and CNS-penetrating antiretroviral
therapy on overall survival and survival after diagnosis of HIV encephalopathy.
Methods
The study population included participants from Pediatric AIDS Clinical Trials Group
(PACTG) Protocols 219 and 219C, which were prospective studies designed to evaluate the
long-term effects of HIV infection and inutero and postnatal exposure to antiretroviral therapy.
Between April 1993 and September 2000, infected and uninfected children from more than 80
study sites in the United States were eligible for enrollment in PACTG 219 if they were born
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to HIV-infected mothers enrolled in PACTG perinatal trials or were themselves enrolled in
PACTG perinatal or clinical trials and were younger than 21 years of age at entry. In September
2000, all children in PACTG 219 were encouraged to enroll into PACTG 219C, which
expanded entry criteria to allow all HIV-infected children at the study sites to enroll into the
cohort. These studies were approved by the human subjects review boards at each participating
institution and written informed consent was obtained from each child's parent or legal
guardian. The population eligible for this study included 2398 perinatally HIV-infected
children enrolled in PACTG 219 and 219C between 1993 and 2006 who had at least one
neurological examination.
At each study visit, data on sociodemographic characteristics, clinical diagnoses, antiretroviral
therapies, and CD4 cell measurements were collected. HIV-RNA measurements, however,
were not routinely collected or available before 2000 and were available for only 46% of the
population. We, therefore, could only adjust for HIV-RNA viral load as a potential confounder
in secondary analyses restricted to that subset. Baseline CD4 cell percentage and viral load
were defined as the closest CD4 cell and HIV-RNA measurement recorded either prior to or
a week after the first neurological examination. Neurological diagnoses reported on
neurological examination and diagnoses forms were reviewed by the study pediatric
neurologist, and dates of HIV encephalopathy diagnoses were confirmed. Only HIV
encephalopathy diagnoses assumed to be progressive based on the best available information
for review were included as cases.
HAART exposure was defined as the concomitant use of at least three drugs from at least two
classes of HIV drugs. HIV drugs were classified into three main categories: nucleoside/
nucleotide reverse-transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and
protease inhibitors. In analyses, children could switch from no HAART to HAART when they
initiated a HAART regimen. However, for statistical simplicity, children were considered to
remain on HAART for the length of follow-up after HAART initiation. In the earlier PACTG
219 cohort, actual dates of initiation of medication or dates of changes in the use of medications
were not available. Following previous evaluations of HAART using data from PACTG 219
[7–8], we assumed the midpoint between the visit date at which use of treatment was recorded
and the date of the prior visit to be the date of treatment initiation.
To rank antiretroviral regimens according to their ability to penetrate the CNS, a modified
version of the CNS-penetration-effectiveness rank developed by Letendre et al. [7] was used.
The modification accounts for the total number of antiretroviral drugs in a regimen and has
been used to predict change in CSF HIV-RNA levels [22]. A scale of 1 (lowest penetration)
to 3 (highest penetration) was used to rank each antiretroviral drug (Table 1). A CNS-
penetration score was calculated for each antiretroviral regimen by summing the individual
ranks of each antiretroviral drug included in the regimen. Antiretroviral regimens with scores
less than 4 were classified as low CNS-penetrating regimens, scores of 4–5 were classified as
medium CNS-penetrating regimens, and scores greater than or equal to 6 were classified as
high CNS-penetrating regimens. In analyses, children could switch from low CNS-penetrating
regimens to higher CNS-penetrating regimens. However, for statistical simplicity, once a child
initiated his/her highest CNS-penetrating regimen, he/she was considered to remain on that
regimen for the length of follow-up.
The baseline date for all children was defined as the date of their first neurological examination.
Prevalent cases of HIV encephalopathy were identified as of this baseline date and removed
from subsequent analyses. However, age at diagnosis and subsequent mortality are presented
descriptively for prevalent diagnoses. For the analyses of incident HIV encephalopathy, each
child was followed from his/her baseline date to the date of HIV encephalopathy diagnosis,
death, or his/her last visit before 31 May 2007 (date of closure of PACTG 219C), whichever
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came first. For overall survival analyses, each child was followed from his/her baseline date
to date of death, or censored as of his/her last visit before study closure. For analyses of survival
after HIVencephalopathy diagnosis, all children with an incident diagnosis of HIV
encephalopathy were followed from their date of HIV encephalopathy diagnosis to their date
of death or censored as of their last study visit. The rate of loss to follow-up in the HIV-infected
children enrolled in the PACTG 219C study was 3–4% per year [23].
Extended Cox regression models were used to estimate the effects of time-varying HAART
versus no HAART on the incidence of HIVencephalopathy, overall survival, and survival after
HIV encephalopathy diagnosis. Extended Cox regression models were also used to estimate
the effects of time-varying medium and high CNS-penetrating regimens versus low CNS-
penetrating regimens on the incidence of HIVencephalopathy, overall survival, and survival
after HIVencephalopathy diagnosis. Age at baseline, sex, race/ethnicity, birth weight, and
baseline CD4 cell percentage were included as covariates in all models. In secondary analyses,
extended Cox models were used to evaluate the effect of HAART and CNS-penetrating
regimens on HIV encephalopathy adjusting also for HIV-RNA and to investigate the effect of
HIV encephalopathy diagnosis on mortality. Analyses were conducted using SAS version 9
(SAS Institute, Cary, North Carolina, USA).
Results
Of the 3553 HIV-infected children enrolled in PACTG 219 and 219C, 3193 were perinatally
infected and 2398 of these (75%) had at least one neurological examination. The perinatally
HIV-infected children with a neurological examination were generally similar to the 795
without, although those excluded were more likely to be female children, of older age, and to
have higher CD4 cell percentage levels. At baseline, 126 cases of HIV encephalopathy were
identified among 2398 children with a neurological examination, resulting in a prevalence of
5.3% [95% confidence interval (CI) 4.4–6.2%]. The median age at diagnosis of these prevalent
cases was 1.7 years (Q1, Q3: 0.9, 3.9). Twenty of the 126 prevalent cases (16%) had initiated
HAART before diagnosis, 60 (48%) had initiated non-HAART regimens, and 46 (36%) had
not initiated any antiretroviral therapy before diagnosis of HIV encephalopathy. There were
42 deaths among the 126 prevalent cases with a median survival after diagnosis of 1.4 years
(Q1, Q3: 0.7, 2.9). The majority of the deaths (62%) occurred among children who never
initiated HAART during their lifetime.
The baseline characteristics of the 2272 children followed for incident HIV encephalopathy
and overall survival analyses are provided in Table 2. Half of the children were female, 48%
were less than or equal to 5 years of age at the time of their first neurological examination,
82% were born prior to 1995, 55% were black, 24% were classified as having low birth weight
(<2500 g), and 19% had severe immunosuppression (CD4 cell <15%). Of the 1044 children
with HIV-RNA information at baseline, 16% had viral load of at least 100 000 copies/ml. At
the time of their first neurological examination, 35% of the children were on a HAART regimen
and 27% were on a high CNS-penetrating regimen.
Over a median duration of 6.4 years of follow-up, (Q1, Q3: 3.6, 9.9), 77 incident cases of HIV
encephalopathy occurred, yielding an incidence rate of 5.1 cases per 1000 person-years (95%
CI 4.0–6.3, person years: 15 178). The median age at diagnosis of the 77 incident cases was
6.3 years (Q1, Q3: 3.3, 11.4). In Fig. 1, the incidence rates and the percentage of children on
HAART in the study population are summarized from 1994–2006. Beginning in 1996, there
was a 10-fold decrease in the incidence of HIVencephalopathy followed by a relatively stable
incidence rate after 2002. Conversely, there was a significant increase in the percentage of
children on HAART regimens after 1996, suggesting an impact of HAART on the decreased
incidence of HIV encephalopathy over time. By the end follow-up, 1806 children (79%) had
Patel et al. Page 5













initiated HAART and 31 of the 77 HIV encephalopathy cases (40%) were observed among
them. Four hundred and sixty-six children never initiated HAART with 46 of the 77 HIV
encephalopathy cases (60%) observed among them. Of the 1741 children who had initiated a
high CNS-penetrating antiretroviral regimen by end of follow-up, 34 (2%) had a diagnosis of
HIV encephalopathy. Twenty-four (9%) of the 267 children who ended follow-up on a medium
CNS-penetrating regimen had a diagnosis of HIV encephalopathy, and 19 (7%) of the 264
children on a low CNS-penetrating regimen had a diagnosis of HIV encephalopathy by end of
follow-up.
Over a median follow-up of 6.5 years (Q1, Q3: 3.9, 10) from the first neurologic examination
until death or censoring, 207 deaths were reported, resulting in a mortality rate of 13.5 per 1000
person-years (95% CI 11.7–15.4, person-years = 15 389). By the end of follow-up, 1826
children had initiated HAART and 101 deaths (6%) were observed among them. The number
initiating HAART is higher than that reported above for the HIV encephalopathy incidence
analysis as some children initiated HAART after their diagnosis. Four hundred and forty-six
children never initiated HAART and 106 deaths (24%) were observed among them. Of the
1756 children who had initiated a high CNS-penetrating regimen, 111 (6%) had died by the
end of follow-up. Twenty-six deaths (10%) were observed among 255 children on a medium
CNS-penetrating regimen and 70 deaths (27%) were observed among 261 children on a low
CNS-penetrating regimen.
The total person-time accrued for the 77 incident cases followed for survival was 219 person-
years. Forty-three deaths were observed during follow-up resulting in a mortality rate of 196.3
per 1000 person-years (95% CI 142.1–264.5). Median survival after diagnosis was 2.0 years
(Q1, Q3: 0.1, –). By the end of follow-up, 51 of the 77 children with a diagnosis of HIV
encephalopathy had initiated HAART and 18 deaths were observed among them, as compared
with 25 deaths among the 26 children who never initiated HAART. The numbers of deaths
occurring by level of CNS-penetrating regimen were 19, 11, and 13 among 50, 12, and 15
children ending follow-up on a high, medium, or low-penetrating regimen.
Children who initiated HAART had a 50% lower risk of developing HIV encephalopathy
compared with those who were not on HAART (hazard ratio 0.50, 95% CI 0.29–0.86) (Table
3). Baseline CD4 cell values less than 15% were associated with a greater than eight-fold
increased risk of HIV encephalopathy (hazard ratio 8.41, 95% CI 4.79–14.76). Age less than
or equal to 1 year at first neurologic examination was also independently associated with a
greater than three-fold increase in HIV encephalopathy with a hazard ratio of 3.38 (95% CI
1.36–8.44). In the secondary analysis restricted to the subset of the population with HIV-RNA
measurements, the HIV encephalopathy hazard ratio comparing HAART to no HAART was
even stronger, 0.32 (95% CI 0.12–0.85) after adjustment for viral load. We also considered
adjustment for calendar year, but treatment effects were attenuated and became nonsignificant
due to the high correlation between calendar year and introduction of HAART (analyses not
presented).
High CNS-penetrating regimens, as defined by CNS-penetrating scores, were associated with
a 41% reduced incidence of HIV encephalopathy compared with low-penetrating regimens,
although this association was not statistically significant (hazard ratio 0.59, 95% CI 0.31–1.10;
Table 3). After adjustment for viral load, the effect of high CNS-penetrating regimens on
incidence of HIV encephalopathy was even stronger compared with low CNS-penetrating
regimens (hazard ratio 0.41, 95% CI 0.13–1.29). Given the restricted sample size in this
subanalysis, this large protective association was not statistically significant. Similar to the
HAART analyses, these treatment effects were attenuated with adjustment for calendar year
due to the correlation between calendar year and introduction of effective CNS-penetrating
regimens (analyses not presented).
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In the overall population, HAART and effective CNS-penetrating regimens were associated
with increased survival compared with no HAART and low CNS-penetrating regimens,
respectively (Table 4). Children with a diagnosis of HIVencephalopathy, however, had 12
times the risk of death compared with children without a diagnosis of encephalopathy (hazard
ratio 12.42, 95% CI 8.46–18.24). Among the 77 children with an incident diagnosis of
HIVencephalopathy, HAART use halved the risk of death after diagnosis compared with non-
HAART regimens (hazard ratio 0.51, 95% CI 0.25–1.05), but use of high CNS-penetrating
regimens conferred a larger survival benefit (74% reduction in risk of death) after HIV
encephalopathy diagnosis compared with low CNS-penetrating regimens (hazard ratio 0.26,
95% CI 0.11–0.61; Table 4).
Discussion
The present study describes a 10-fold decrease in the incidence of HIV encephalopathy among
a large prospective cohort of perinatally infected children enrolled over a 14-year period, 1993–
2006. This dramatic decline in incidence occurred with a concurrent increase in use of HAART,
proposing an association between HAART use and risk of HIV encephalopathy. Although this
hypothesis has been suggested by previous studies [13,24], this is the first study to quantify
the impact of HAART on the incidence of HIV encephalopathy.
We found HAART use to decrease the risk of HIV encephalopathy by 50% compared with no
HAART use. Similar to previous studies [8,9], we also found HAART use to be associated
with improved overall survival compared with no HAART use. HAART also resulted in an
improvement in survival after diagnosis of HIV encephalopathy, although this association was
not statistically stable due to the small sample size of incident cases. These results suggest that
HAART inhibits or delays HIV dissemination in the CNS and may also decrease viral
replication if an active and persistent infection is already established in the brain.
One study found a significant decrease in CNS viral load with increasing numbers of CNS-
penetrating antiretroviral drugs independent of HAART alone [25]. We evaluated the effect of
CNS-penetrating regimens on the risk of HIV encephalopathy and found effective CNS-
penetrating regimens to be associated with a lower incidence of HIV encephalopathy, although
not statistically significant. However, we did observe a significant survival benefit of using
high CNS-penetrating regimens after diagnosis of HIV encephalopathy. Optimal levels of
antiretroviral drugs within the CNS, over what some HAART regimens provide, are likely
needed to stop the active replication of HIV within the brain that can lead to further neurological
decline and eventually death. Although the utility of effective CNS-penetrating antiretroviral
drugs is clear in improving survival after diagnosis of HIV encephalopathy, a study assessing
the impact of such drugs on cognitive impairment was equivocal [26]. Further research is
required to assess the impact of antiretroviral CNS-penetration effectiveness on the various
pathogenic mechanisms leading to neurological deterioration and disease.
A recent study evaluating the ability of the protease inhibitor atazanavir to penetrate the CNS
[27] found cerebrospinal concentrations of atazanavir to be highly variable even when boosted
with ritonavir. This result suggests a modification of the CNS-penetration-effectiveness ranks
proposed by Letendre et al. [7]. Given that only 1% of the children classified as initiating a
high CNS-penetrating regimen in our study used atazanavir boosted with ritonavir, any future
modification of the ranking system is unlikely to change our results.
Our study population only included children with at least one neurological examination in
PACTG 219 or 219C. This inclusion criterion allowed identification of preexisting diagnoses
of HIV encephalopathy by a pediatric neurologist and subsequent follow-up after the first
examination of confirmed ‘disease-free’ children at risk for incident HIVencephalopathy.
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However, this inclusion criterion did exclude 795 perinatally infected children who did not
have a neurological examination in PACTG 219 or 219C. This excluded population had
significantly more female children and higher CD4 cell percentage compared with the study
population. They also were significantly older than the study population. Although sex was
not associated with risk of HIVencephalopathy in our analyses, the associations of age and
CD4 cell percentage with risk of HIVencephalopathy suggest that the excluded population
would have a lower risk of HIVencephalopathy compared with the study population.
The children in our study population were not followed from birth. Therefore, early fatal cases
of HIV encephalopathy may have been missed leading to an underestimation of the incidence
of HIV encephalopathy. The median age of the incident cases of HIV encephalopathy identified
during follow-up was also greater than the median age of the prevalent cases of HIV
encephalopathy identified at baseline, suggesting that a ‘survivor’ cohort of children was
followed for incident analyses. If these ‘survivors’ were at lower risk of HIV encephalopathy
compared with the general pediatric HIV-infected population, then the estimated incidence
rates of HIV encephalopathy may also be underestimated. Our interest in the trend in incidence
of HIV encephalopathy over time, however, would not be affected by this potential survivor
effect.
As viral load information was missing for 46% of the study population, we were not able to
adjust for this important confounder in our primary analyses. Sensitivity analyses conducted
among the subset of children with viral load information suggest that stronger protective effects
of HAART and high CNS-penetrating regimens on risk of HIV encephalopathy and survival
after diagnosis of HIV encephalopathy would have been estimated with adjustment of viral
load. However, as clinicians did not have viral load information to make treatment decisions
in the early years of follow-up, viral load could not be a confounder in these time periods.
Diagnoses of HIV encephalopathy were collected in the study population either from chart
abstraction or from neurological examination forms. It is unclear whether diagnoses collected
from chart abstraction were made by treating clinicians or pediatric neurologists. Given the
wide spectrum of neurological disease experienced by perinatally infected children, there may
be some outcome misclassification of HIV encephalopathy. Assuming that this
misclassification is nondifferential with respect to treatment, our observed protective effects
of HAART and CNS-penetrating antiretroviral regimens on risk of HIV encephalopathy and
survival after diagnosis of HIV encephalopathy, respectively, are conservative estimates.
In conclusion, HAART use was highly effective in reducing the risk of HIV encephalopathy
among perinatally infected children and adolescents. Among children with a diagnosis of
HIVencephalopathy, treatment decisions should consider the effectiveness of antiretroviral
drugs in penetrating the CNS. Highly CNS-penetrating regimens conferred a substantial
survival benefit to children with HIV encephalopathy compared with low CNS-penetrating
regimens. Of course, any potential toxicity of individual or combination antiretroviral drugs
[28] must be weighed with their ability to penetrate the CNS when making treatment decisions
in pediatric HIV-infected populations.
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Table 1
Central nervous system penetration scale for antiretroviral drugs.
1 (lowest penetration) 2 (medium penetration) 3 (highest penetration)
Didanosine (ddI) Emtricitabine (FTC) Abacavir (ABC)
Tenofovir (TFV) Lamivudine (3TC) Zidovudine (ZDV)
Zalcitabine (ddC) Stavudine (d4T) Delavirdine (DLV)
Nelfinavir (NFV) Efavirenz (EFV) Nevirapine (NVP)
Ritonavir (RTV) Amprenavir (APV) Amprenavir/ritonavir (APV-r)
Saquinavir (SQV) Atazanavir (ATV) Atazanavir/ritonavir (ATV-r)
Saquinavir/ritonavir (SQV-r) Fosamprenavir (f-APV) Fosamprenavir/ritonavir (f-APV-r)
Tipranavir/ritonavir (TPV-r) Indinavir (IDV) Indinavir/ritonavir (IDV-r)
Enfuvirtide (T-20) Lopinavir/ritonavir (LPV-r)
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Table 2
Characteristics of study population followed for incident HIV encephalopathy and overall survival at time of
first neurologic examination (N = 2272).
Characteristic N (%)
Sex
    Male 1136 (50)
    Female 1136 (50)
Age
    ≤1 year 268 (12)
    2–5 years 828 (36)
    6–10 years 833 (37)
    >10 years 343 (15)
Birth year
    <1990 874 (38)
    1990–1994 996 (44)
    >1995 402 (18)
Race/ethnicity
    White, Non-Hispanica 342 (15)
    Black, Non-Hispanic 1247 (55)
    Hispanic 683 (30)
Birth weight
    <2500 g 551 (24)
    ≥2500 g 1640 (72)
    Unknown 81 (4)
CD4 cell percentage
    <15 433 (19)
    15–24 505 (22)
    ≥25 1271 (56)
    Missing 63 (3)
HIV-RNA load (copies/ml)
    ≤400 327 (14)
    401–99 999 550 (24)
    ≥100 000 167 (7)
    Missing 1228 (54)
Antiretroviral therapy
    HAART 786 (35)
    Non-HAART 1486 (65)
CNS-penetrating regimens
    Low 896 (39)
    Medium 765 (34)
    High 611 (27)
CNS, central nervous system.
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a
Other race/ethnicity (N = 36) included in White, Non-Hispanic category.
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Table 3
Estimated effects of HAART and central nervous system-penetrating antiretroviral regimens on incident HIV
encephalopathy.
Characteristic Hazard ratioa (95% CI) P
Antiretroviral therapy
    HAART 0.50 (0.29, 0.86) 0.01
    Non-HAART Referent
CNS-penetrating regimens
    Low Referent
    Medium 0.86 (0.46, 1.62) 0.64
    High 0.59 (0.31, 1.10) 0.10
CI, confidence interval; CNS, central nervous system.
a
Multivariate hazard ratios adjusted for age, sex, race, birth weight, and CD4 cell percentage at baseline.
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Table 4
Estimated effects of HAART and central nervous system-penetrating antiretroviral regimens on overall survival
and survival after diagnosis of incident HIV encephalopathy.
Characteristic Hazard ratioa (95% CI) P
Effect on overall survival in the entire cohort (N = 2272)
    Antiretroviral therapy
        HAART 0.41 (0.29, 0.58) <0.0001
        Non-HAART Referent
    CNS-penetrating regimens
        Low Referent
        Medium 0.25 (0.16, 0.40) <0.0001
        High 0.31 (0.22, 0.45) <0.0001
Effect on survival after diagnosis of HIV encephalopathy (N = 77)
    Antiretroviral therapy
        HAART 0.51 (0.25, 1.05) 0.07
        Non-HAART Referent
    CNS-penetrating regimens
        Low Referent
        Medium 0.51 (0.20, 1.33) 0.17
        High 0.26 (0.11, 0.61) 0.002
CI, confidence interval; CNS, central nervous system.
a
Each adjusted for age, sex, race, birth weight, and CD4 cell percentage.
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